medical affairs teams

5.7.2013

Regulatory and Compliance Functions Within Medical Affairs Teams

Over the past several years, we have seen a slow shift among regulatory affairs and compliance groups in the pharmaceutical industry as these groups move under medical affairs oversight. This hasn’t been a surprise among many industry observers, but it hasn’t...
 

5.1.2013 Medical Affairs

Product Launch: A Busy Time for Medical Affairs Teams

Marketing and commercial teams get a lot of the credit for a successful product launch, but medical affairs teams are typically buzzing with activity in the months (sometimes even years) preceding drug approval.  As the official communication channel between a...
 

4.29.2013 KOL Management

Driving KOL Engagement Efficiency through Physician-Interaction Databases

Cutting Edge Information recently conducted research among pharmaceutical medical affairs groups that looked at physician-interaction database ownership.  The research revealed that ownership of these databases varies among the surveyed companies.  Global groups...
 

4.8.2013 Medical Affairs

Product Development Stage Dictates Medical Affairs Spending Patterns

Although marketing and market access functions may not support a developing drug until Phase 2 or even later, companies need to coordinate between several different teams as products move through different development stages beginning in the pre-clinical stage....
 

4.4.2013 Medical Affairs

Technology’s Role in Enhancing and Expanding Medical Information Teams’ Capabilities

Within companies’ medical affairs groups, medical information subfunctions disseminate information quickly across consumer and healthcare practitioner audiences alike.  However, US companies rely on different-sized medical information teams to fulfill these...
 

4.1.2013 Medical Affairs

Asia and the Medical Affairs Function

Regardless of company size, establishing operations to support expansions in new territories has a big impact on existing organizational structures.  The question often rests on how the subsidiary will be connected to the headquarters. Will it be a centralized...
 

2.13.2013 IIT Studies

Oncology IITs – Pair with Research Organizations for Success

In high-pressure therapeutic areas such as oncology, a new model for investigator initiated trials (IITs) is becoming more popular among pharmaceutical companies. Rather than going through an in-house medical grants process to fund IITs, some companies are joining...
 

1.18.2013 Medical Affairs

Medical Publications Teams Worthy of Funding

With tightening restrictions on how marketing and sales reps can interact with physicians, medical publication has become a vital task for communicating clinical information from drug companies to physicians. While publications help companies reach anywhere from...
 

12.12.2012 Medical Affairs

MSL Teams Face a Battle on Two Fronts to Prove Their Value to Companies

As with any industry team, medical science liaisons (MSLs) must convince their bosses that the department — and their jobs — is worth the effort and funding that go into it. For MSL teams, however, convincing upper management and key stakeholders is only half...
 

12.11.2012 Medical Affairs

Industry Adopting KOL Feedback Surveys as a Primary Means of Measuring MSL Performance

Recent research reveals that thought leader feedback surveys have become a standard means of the Medical Affairs and Medical Science Liaison performance measurement, a trend that has experienced tremendous growth in just a few years. Research shows that overall,...